Literature DB >> 7854522

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.

M Filippi1, D W Paty, L Kappos, F Barkhof, D A Compston, A J Thompson, G J Zhao, C M Wiles, W I McDonald, D H Miller.   

Abstract

We obtained two conventional unenhanced T2-weighted brain MRI scans, separated by an interval of 24 to 36 months, in 281 patients with multiple sclerosis (MS). At the time of each scan, clinical disability was rated using the Kurtzke Expanded Disability Status Scale (EDSS). Changes in disability between the two examinations correlated weakly but significantly with the number of new (Spearman's rank correlation coefficient = 0.13; p = 0.02) and enlarging (Spearman's rank correlation coefficient = 0.18; p = 0.002) MRI lesions. This result suggests that brain T2-weighted MRI is a useful supplementary marker of disease activity in definitive (phase III) clinical treatment trials in MS.

Entities:  

Mesh:

Year:  1995        PMID: 7854522     DOI: 10.1212/wnl.45.2.255

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  Multiple sclerosis normal-appearing white matter: pathology-imaging correlations.

Authors:  Natalia M Moll; Anna M Rietsch; Smitha Thomas; Amy J Ransohoff; Jar-Chi Lee; Robert Fox; Ansi Chang; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

3.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 4.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

5.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

Review 6.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 7.  Epidemiology of disabling neurological disease: how and why does disability occur?

Authors:  D T Wade
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

8.  MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.

Authors:  M L Gawne-Cain; J I O'Riordan; A Coles; B Newell; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

9.  Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

Authors:  Marco Rovaris; Giancarlo Comi; David Ladkani; Jerry S Wolinsky; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

10.  Relevance of the skewness index in DTI exploration of multiple sclerosis.

Authors:  Eliane Graulières; Jean-Albert Lotterie; Emmanuelle Cassol; Angélique Gerdelat; Michel Clanet; Isabelle Berry
Journal:  MAGMA       Date:  2008-11-08       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.